Competitive Intelligence
Weekly Competitive Intelligence Briefing: Ozempic
Week ending November 15, 2026
1. Competitive landscape snapshot
AI answers about Ozempic named nine competitors. Wegovy led with 49 mentions, followed by Mounjaro (28) and Trulicity (27). Zepbound (15) and Rybelsus (13) formed the next tier; Saxenda (12), Victoza (11), Bydureon (3), and Byetta (1) were peripheral.
The strongest explicit comparison signals were:
- Wegovy: 7 direct responses to the question “What’s the difference between Ozempic and Wegovy?” The remaining mentions were largely incidental to questions about dosing, weight-loss indications, alternatives, and product visibility.
- Mounjaro: At least 14 mentions came from two direct comparison questions: switching from Ozempic to Mounjaro and comparing Ozempic’s labeled benefits with Mounjaro/Trulicity.
- Trulicity: At least 14 mentions came from the direct efficacy question and the labeled-benefits comparison.
- Rybelsus: 7 mentions came from the direct side-effect/warnings comparison.
Overall, Ozempic remains the reference brand in a broad GLP-1 comparison set rather than appearing as one competitor among equals.
2. How the comparison is currently framed
Wegovy is framed as a close product relative, not a fundamentally different competitor. Answers consistently emphasize the shared semaglutide ingredient while distinguishing approved use and dosing. The recurring framing is “same active ingredient, different indication/formulation,” which is broadly neutral. However, several answers also connect Ozempic with off-label weight-loss use, reinforcing overlap between the brands.
Trulicity comparisons favor Ozempic. All seven responses to the efficacy question described Ozempic as generally perceived as more effective, particularly for A1C reduction and weight loss. One excerpt states that the perception “isn’t purely marketing” and has “solid trial data” behind it. Six of the seven responses paired the Trulicity comparison with superiority-coded language such as “stronger,” “best,” or “more effective.” The framing is favorable to Ozempic but usually hedged by endpoint and individual-response caveats.
Mounjaro is the clearest competitor-favorable comparison. Responses consistently explain Mounjaro’s dual GIP/GLP-1 mechanism and often associate it with “greater appetite/weight effects.” All seven switch-comparison responses carried “stronger” language, making this the most consistent competitor-advantage narrative in the set.
Rybelsus is framed neutrally: same active ingredient and broadly similar warnings, with differences attributed mainly to oral versus injectable administration.
3. Movers — who’s gaining or losing ground
Week over week, Zepbound increased from 12 to 15 (+3), the largest gain; Mounjaro rose from 26 to 28 (+2), while Trulicity and Rybelsus each gained one mention. Wegovy declined from 52 to 49 (-3), and Bydureon fell from 6 to 3 (-3). Victoza fell by one and Byetta by two.
The longer trend still shows sustained expansion for the major challengers: since July 12, Mounjaro rose from 8 to 28, Trulicity from 6 to 27, Zepbound from 4 to 15, and Rybelsus from 3 to 13. Wegovy also grew substantially from 16 to 49, despite this week’s decline. No new named competitor entered the conversation this week.
4. Questions worth watching
- “Do people typically perceive Ozempic as more effective than Trulicity, or is that mostly marketing?”
- “If someone switches from Ozempic to Mounjaro, what differences in mechanism or expected experience are described?”
- “What’s the difference between Ozempic and Wegovy—same medicine or different brands?”
- “Compared with Trulicity or Mounjaro, what benefits are actually supported by Ozempic’s labeling?”
5. Recommended actions
- Monitor Zepbound and Mounjaro next week for continued gains, given their +3 and +2 weekly increases.
- Flag the Mounjaro comparison as the primary competitive-watch item: AI consistently presents its dual mechanism and stronger weight-related effects.
- Track whether Ozempic’s efficacy advantage over Trulicity persists across future question variants.
- Continue routine monitoring of Wegovy: it remains the dominant named competitor despite a modest weekly decline.